Dexmedetomidine enhances recovery after gastrointestinal cancer surgery by protecting the endothelial glycocalyx: A randomized, double-blind, placebo-controlled study

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 12

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastrointest Surg. Dec 27, 2025; 17(12): 114628
Published online Dec 27, 2025. doi: 10.4240/wjgs.v17.i12.114628

Full Size Figure Download Figure

Figure 3 Interleukin-6 and syndecan-1 levels over time. A: Interleukin-6; B: Syndecan-1. IL-6: Interleukin-6; DEX: Dexmedetomidine.

Citation: Zeng R, Tang CL, Zhao Y, Wang RX, Fang Y, Hu XW. Dexmedetomidine enhances recovery after gastrointestinal cancer surgery by protecting the endothelial glycocalyx: A randomized, double-blind, placebo-controlled study. World J Gastrointest Surg 2025; 17(12): 114628
URL: https://www.wjgnet.com/1948-9366/full/v17/i12/114628.htm
DOI: https://dx.doi.org/10.4240/wjgs.v17.i12.114628

Zeng R, Tang CL, Zhao Y, Wang RX, Fang Y, Hu XW. Dexmedetomidine enhances recovery after gastrointestinal cancer surgery by protecting the endothelial glycocalyx: A randomized, double-blind, placebo-controlled study. World J Gastrointest Surg 2025; 17(12): 114628 [PMID: 41479730 DOI: 10.4240/wjgs.v17.i12.114628]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.